Age-related Macular Degeneration (AMD) Drugs Market Size is valued at USD 9.58 Bn in 2023 and is predicted to reach USD 19.77 Bn by the year 2031 at an 9.7% CAGR during the forecast period for 2024-2031.
Age-related macular degeneration is a degenerative eye disease commonly occurring after the age of 50, leading to vision loss in the inner area of the visual field. There are two types: dry AMD - degeneration of vision due to gradual thinning of the macula; wet AMD - rapid degeneration through unhealthy growth under the retina. Treatment for AMD is primarily aimed at the wet form with anti-vascular endothelial growth factor (anti-VEGF) therapies, including Eylea (aflibercept), Lucentis (ranibizumab), and new Vabysmo (faricimab). In 2023, the FDA authorized Syfovre, the inaugural medicine for treating dry age-related macular degeneration (AMD). Syfovre is the first treatment to receive FDA approval, having shown a reduction of around 20% in the progression of blind spots associated with advanced dry macular degeneration over a two-year period.
Major drivers for the AMD drug market include an increasing emphasis on research and development. New formulations and delivery systems are developed to minimize side effects, enhance treatment effectiveness, and enhance compliance by either extending dosing intervals or offering alternative delivery mechanisms. Additionally, novel therapies for wet and dry AMD will propel future market growth by bridging unmet medical needs within the studied patient population.
The age-related Macular Degeneration (AMD) Drugs market is segmented by products, molecules, type of AMD, approval type, end user. By products the market is segmented into lucentis, eylea & eylea HD, vabysmo, syfovre, other products. By molecules market is categorized into ranibizumab, aflibercept, faricimab, pegcetoplan, other molecules. By type of AMD market is categorized into wet AMD, dry AMD. By approval type market is segmented into biologic, biosimilar. By end user the market is categorized into hospitals, specialty centers, and long-term care facilities.
The Eylea and Eylea HD segment is a significant driver in the Age-related Macular Degeneration drugs market through its established efficacy, broad acceptance, and continuous innovations that enhance treatment protocols. Through its higher dose (8 mg as opposed to 2 mg), Eylea HD has shown promise in the elongation of treatment intervals, thus making it less burdensome for patients and, therefore, presumably enhancing compliance. Long-term dosing for this kind of drug is part of a strategic approach against competitors like Roche's Vabysmo, which has the benefit of doing once a month. These developments and research into new formulations and delivery systems position Regeneron at the competitive edge in AMD drugs. All these factors ensure Eylea and Eylea HD remain the frontier AMD treatments, driving up market growth and leading to future choices in therapeutics.
The Dry AMD segment is expected to grow considerably in the market for drugs targeted at treating age-related macular degeneration (AMD). Recent FDA approvals, with a strong pipeline of new therapies and growing prevalence, will propel the Dry AMD segment forward. Approvals over 2023 for such key therapies as Pegcetacoplan in Syfovre and Avacincaptad Pegol in IZERVAY indicated the need for effective treatments for dry AMD and infused confidence in the market, attracting still further investment. But finally, promising pipelines in terms of peptide derivatives and gene therapies from companies like Alkeus Pharmaceuticals and Belite Bio bode well for future progress. Dry AMD accounts for almost 90% of all cases of AMD and is increasing with global aging; hence, it is an important segment and encourages pharmaceutical companies to act fast, accelerate new treatments, and ensure big returns.
North America leads in this market, largely due to a high incidence rate of AMD, high pharmaceutical R&D capabilities, and multiple available therapies. Regionally, the market is experiencing increased unmet needs, with nearly 200,000 new cases diagnosed each year. Similarly, strong R&D investments are made in North America, and as a result, some major pharmaceutical research-oriented institutes are also present there; for example, the recent approval of biosimilar Enzeevu for treating wet AMD. Apart from this, numerous treatment options are available, including Eylea, Lucentis, Vabysmo, and Syfovre, which places all patients at a developed level of care.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 9.58 Bn |
|
Revenue Forecast In 2031 |
USD 19.77 Bn |
|
Growth Rate CAGR |
CAGR of 9.7 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Products, Molecules, Type of AMD, Approval type, End User and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; Southeast Asia |
|
Competitive Landscape |
Regeneron Pharmaceuticals Inc. (US), Bayer AG (Germany), F. Hoffmann-La Roche AG (Switzerland), Novartis AG (Switzerland), Apellis Pharmaceuticals, Inc. (US), Coherus BioSciences, Inc. (US), Astellas Pharma Inc. (Japan), Biogen (US), STADA Arzneimittel AG (Germany), Formycon AG (Germany), Biocon. (India), Outlook Therapeutics, Inc. (US), Intas Pharmaceuticals Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Chengdu Kanghong Biotech Company (China), Sandoz Group AG (Switzerland), Stealth BioTherapeutics Inc. (US), Ocular Therapeutix, Inc. (US), Opthea Limited, Inc. (Australia), Kodiak Sciences Inc. (US), Innovent Biologics, Inc. (China), Bio-Thera Solution Inc. (China), Alvotech (Iceland), Alteogen Inc. (South Korea), Shanghai Henlius Biotech, Inc. (China), Amgen Inc. (US), Ocumension Therapeutics. (China) and Adverum Biotechnologies, Inc. (US) |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Age-related Macular Degeneration (AMD) Drugs Market by Products -
Age-related Macular Degeneration (AMD) Drugs Market by Molecules -
Age-related Macular Degeneration (AMD) Drugs Market by Type of AMD -
Age-related Macular Degeneration (AMD) Drugs Market by Type of Approval type -
Age-related Macular Degeneration (AMD) Drugs Market by End User -
Age-related Macular Degeneration (AMD) Drugs Market by Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
